Results 41 to 50 of about 81,769 (261)

Angiogenesis in Glioblastoma [PDF]

open access: yesNew England Journal of Medicine, 2013
Recent work suggests that glioblastoma cells can differentiate into endothelial cells and pericytes, thus providing a means of tumor vascularization.
Sunit, Das, Philip A, Marsden
openaire   +2 more sources

The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ‐dependent inhibition of the AKT pathway

open access: yesEMBO Molecular Medicine, 2016
A variety of drugs targeting monoamine receptors are routinely used in human pharmacology. We assessed the effect of these drugs on the viability of tumor‐initiating cells isolated from patients with glioblastoma.
Suzana Assad Kahn   +18 more
doaj   +1 more source

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy

open access: yesJournal of Experimental & Clinical Cancer Research, 2021
Immunotherapy is currently under intensive investigation as a potential breakthrough treatment option for glioblastoma. Given the anatomical and immunological complexities surrounding glioblastoma, lymphocytes that infiltrate the brain to develop durable
Jorrit De Waele   +7 more
doaj   +1 more source

Treatment of Glioblastoma [PDF]

open access: yesJournal of Oncology Practice, 2017
Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity. Despite ongoing research, there has not been improvement in survival in glioblastoma.
Joo Yeon, Nam, John F, de Groot
openaire   +2 more sources

Abnormal Schwannoma-like Growth of multiple, multifocal BRAF V600E-positive Glioblastoma in the Interior Acoustic Canal with Leptomeningeal Infiltration: a case report

open access: yesJournal of Medical Case Reports, 2022
Background Glioblastoma belongs to the most common and most aggressive tumor entity of the central nervous system with a poor prognosis of only few months.
Roopa Jayarama-Naidu, Evelyn Gallus
doaj   +1 more source

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

open access: yesFrontiers in Immunology, 2022
Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades.
Paris M. Kollis   +20 more
doaj   +1 more source

The Glioblastoma CircularRNAome

open access: yesInternational Journal of Molecular Sciences, 2023
Glioblastoma remains one of the most aggressive cancers of the brain, warranting new methods for early diagnosis and more efficient treatment options. Circular RNAs (circRNAs) are rather new entities with increased stability compared to their linear counterparts that interact with proteins and act as microRNA sponges, among other functions.
Alexandru Tirpe   +8 more
openaire   +2 more sources

The role of the Bmi1-GSK3β pathway in glioblastoma [PDF]

open access: yes, 2010
Malignant gliomas remain one of the deadliest of all cancers despite maximal therapy. They present unique challenges to therapy with a median survival of 12 months.
Korur, Serdar
core   +1 more source

Extracellular vesicles originating from glioblastoma cells increase metalloproteinase release by astrocytes: the role of CD147 (EMMPRIN) and ionizing radiation

open access: yesCell Communication and Signaling, 2020
Background Glioblastoma multiforme is an aggressive primary brain tumor that is characterized by local invasive growth and resistance to therapy. The role of the microenvironment in glioblastoma invasiveness remains unclear.
Nicholas W. Colangelo, Edouard I. Azzam
doaj   +1 more source

EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice [PDF]

open access: yes, 2005
Background: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer. With the available treatments, survival does not exceed 12–14 mo from the time of diagnosis.
Levitzki, Alexander   +15 more
core   +2 more sources

Home - About - Disclaimer - Privacy